Compugen (CGEN) SVP sells 2,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Compugen Ltd SVP of Business Development Zurit Levine exercised options and sold shares in a pre-planned transaction. On April 24, 2026, she exercised 2,000 share options at $1.15 per share and sold 2,000 ordinary shares at $3.20 per share in an open-market sale pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025. Following these transactions, she directly held 29,375 ordinary shares.

Insider Trade Summary 10b5-1

Net Seller: 2,000 shares ($6,400)

Net Sell 3 txns

Insider Levine Zurit

Role SVP, Business Development

Sold 2,000 shs ($6K)

Type	Security	Shares	Price	Value
Exercise	Share Option (right to buy)	2,000	$0.00	--
Exercise	Ordinary Shares	2,000	$1.15	$2K
Sale	Ordinary Shares	2,000	$3.20	$6K

Holdings After Transaction: Share Option (right to buy) — 52,000 shares (Direct, null); Ordinary Shares — 31,375 shares (Direct, null)

Footnotes (1)

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

Key Figures

Shares sold: 2,000 shares Sale price: $3.20 per share Options exercised: 2,000 shares +4 more

7 metrics

Shares sold 2,000 shares Ordinary Shares sold at $3.20 on April 24, 2026

Sale price $3.20 per share Open-market sale of 2,000 Ordinary Shares

Options exercised 2,000 shares Exercise of options into Ordinary Shares

Exercise price $1.15 per share Share Option (right to buy) conversion price

Post-transaction holdings 29,375 shares Ordinary Shares directly owned after transactions

Trading plan adoption date December 23, 2025 Rule 10b5-1 trading plan for reported sale

Option expiration August 3, 2033 Expiration date for exercised Share Option grant

Key Terms

Rule 10b5-1 trading plan, Share Option (right to buy), derivative security, open-market sale

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Share Option (right to buy) financial

"security_title: "Share Option (right to buy)" for the derivative transaction"

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

open-market sale financial

"transaction_action: "open-market sale" for the 2,000 Ordinary Shares"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levine Zurit

(Last) (First) (Middle)

C/O COMPUGEN LTD.

26 HAROKMIM STREET

(Street)

HOLON 5885849

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
COMPUGEN LTD [ CGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Business Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/24/2026		M(1)		2,000	A	$1.15	31,375	D
Ordinary Shares	04/24/2026		S(1)		2,000	D	$3.2	29,375	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$1.15	04/24/2026		M(1)			2,000	(2)	08/03/2033	Ordinary Shares	2,000	$0	52,000	D

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025.

2. This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

	/s/ Zurit Levine	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Compugen (CGEN) SVP Zurit Levine report?

Zurit Levine reported exercising options for 2,000 ordinary shares and selling 2,000 ordinary shares. The sale was an open-market transaction executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025, providing structure and automation to the trading activity.

How many Compugen (CGEN) shares did the SVP sell and at what price?

The SVP, Zurit Levine, sold 2,000 ordinary shares of Compugen at $3.20 per share. This was reported as an open-market or private transaction sale and formed part of a broader set of transactions on April 24, 2026, under her trading plan.

What options did the Compugen (CGEN) SVP exercise in this Form 4?

Levine exercised options to acquire 2,000 ordinary shares at an exercise price of $1.15 per share. These options were part of a grant that vested 25% on September 30, 2024, with the remainder vesting in 12 equal quarterly installments, subject to continued service.

How many Compugen (CGEN) shares does Zurit Levine own after these transactions?

After the reported transactions, Zurit Levine directly owned 29,375 ordinary shares of Compugen. This figure reflects her holdings following the exercise of 2,000 options and the sale of 2,000 ordinary shares as disclosed for the April 24, 2026 activity.

Was the Compugen (CGEN) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Zurit Levine on December 23, 2025. Such plans allow insiders to schedule trades in advance according to predefined instructions and timing.

What are the vesting terms of the Compugen (CGEN) option exercised by the SVP?

The option exercised vested 25% on September 30, 2024. The remaining portion vested or vests in 12 equal quarterly installments thereafter, conditioned on the SVP’s continued service to Compugen, as described in the footnote to the insider transaction disclosure.